BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive eithertrametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. RESULTS:Median progression-free survival was 4.8 months in the trametinib group and 1.5 months in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). At 6 months, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P=0.01). Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose reduction; asymptomatic and reversible reduction in the cardiac ejection fraction and ocular toxic effects occurred infrequently. Secondary skin neoplasms were not observed. CONCLUSIONS: Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials.gov number, NCT01245062.).
RCT Entities:
BACKGROUND: Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived. In previous trials, MEK inhibition appeared to be promising in this population. METHODS: In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600KBRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio. Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib. Progression-free survival was the primary end point, and overall survival was a secondary end point. RESULTS: Median progression-free survival was 4.8 months in the trametinib group and 1.5 months in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001). At 6 months, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P=0.01). Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose reduction; asymptomatic and reversible reduction in the cardiac ejection fraction and ocular toxic effects occurred infrequently. Secondary skin neoplasms were not observed. CONCLUSIONS:Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAFV600E or V600K mutation. (Funded by GlaxoSmithKline; METRIC ClinicalTrials.gov number, NCT01245062.).
Authors: Alexander K Tsai; Asra Y Khan; Christina E Worgo; Lucy L Wang; Yuanyuan Liang; Eduardo Davila Journal: Cancer Immunol Res Date: 2017-08-03 Impact factor: 11.151
Authors: Michael R Burgess; Eugene Hwang; Ari J Firestone; Tannie Huang; Jin Xu; Johannes Zuber; Natacha Bohin; Tiffany Wen; Scott C Kogan; Kevin M Haigis; Deepak Sampath; Scott Lowe; Kevin Shannon; Qing Li Journal: Blood Date: 2014-10-31 Impact factor: 22.113
Authors: Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2017-03-29 Impact factor: 7.038
Authors: V R Belum; K Marulanda; C Ensslin; L Gorcey; T Parikh; S Wu; K J Busam; P A Gerber; M E Lacouture Journal: Ann Oncol Date: 2015-09-19 Impact factor: 32.976
Authors: Susann-Cathrin Schüle; Thomas Kurt Eigentler; Claus Garbe; Christian la Fougère; Konstantin Nikolaou; Christina Pfannenberg Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-18 Impact factor: 9.236
Authors: Anthony W Tolcher; Razelle Kurzrock; Vincente Valero; Rene Gonzalez; Rebecca S Heist; Antoinette R Tan; Julie Means-Powell; Theresa L Werner; Carlos Becerra; Chenxi Wang; Cathrine Leonowens; Shanker Kalyana-Sundaram; Joseph F Kleha; Jennifer Gauvin; Anthony M D'Amelio; Catherine Ellis; Nageatte Ibrahim; Li Yan Journal: Cancer Chemother Pharmacol Date: 2020-02-15 Impact factor: 3.333
Authors: Geoffrey R Oxnard; Peter C Lo; Mizuki Nishino; Suzanne E Dahlberg; Neal I Lindeman; Mohit Butaney; David M Jackman; Bruce E Johnson; Pasi A Jänne Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609